Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients

J. Eisen, Howard; Murat Tuzcu, E.; Dorent, Richard; Kobashigawa, Jon; Mancini, Donna; A. Valantine-von Kaeppler, Hannah; C. Starling, Randall; Sørensen, Keld; Hummel, Manfred; M. Lind, Joan; Abeywickrama, Kamal; Bernhardt, Peter

doi:10.1056/nejmoa022171

Public

Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients

Published in New England Journal of Medicine • Aug 27, 2003

Authors:

Howard J. Eisen

E. Murat Tuzcu

Richard Dorent

Abstract

BACKGROUND: Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may suppress cardiac-allograft vasculopathy. We conducted a randomized, double-blind, clinical trial comparing everolimus with azathioprine in recipients of a first heart transplant. METHODS: A total of 634 patients...

Subject

Everolimus

Medicine

Azathioprine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!